119 results
6-K
EX-99.1
GLPG
Galapagos NV
25 Mar 21
Galapagos appoints Bart Filius as President and Chief Operating Officer
6:00am
development, commercial strategy, finance, human resources, and other business operations.
Bart Filius joined Galapagos in 2014 as Chief Financial … was a strategy consultant at Arthur D. Little. Bart holds an MBA from INSEAD.
Commenting on the promotion, CEO Onno van de Stolpe said, “I’m delighted
6-K
EX-99.1
GLPG
Galapagos NV
31 Mar 23
Current report (foreign)
6:05am
. The transaction is subject to customary closing conditions and is anticipated to close in July 2023.
“Last year, we announced our Forward, Faster strategy … . “This further demonstrates that we are executing on our growth strategy and our ambition to expand our service offering beyond early research. It highlights
6-K
EX-99.1
GLPG
Galapagos NV
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
Exhibit 99.1
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
Clear path forward for accelerated … and current financial investments of €4.4 billion on 30 September
R&D and Strategy Webcast presentation at R&D Update tomorrow in New York, 4 November
6-K
EX-99.3
GLPG
Galapagos NV
11 Apr 22
Current report (foreign)
5:14pm
of our savings program, our global R&D collaboration with Gilead, our collaboration with AbbVie our R&D plans and strategy, including progress on our … fibrosis portfolio, oral therapeutics and SIK platform, and potential changes in such plans and strategy, our commercialization efforts for filgotinib
6-K
EX-99.1
GLPG
Galapagos NV
4 Jan 24
Current report (foreign)
5:32pm
strategy, we are very pleased to collaborate with Thermo Fisher, a leader in accelerating life sciences research and the development of life-changing … .”
“This collaboration marks the start of an exciting journey to support Galapagos with their decentralized manufacturing strategy,” stated Jennifer Cannon
6-K
EX-99.2
4mj90qib2 d1m
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
34n a8tnwp
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.1
4aekha50s
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.3
7wq84guxr3u
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.1
lej pqdcq39
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.2
i891xmvz4i go49eya
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.6
kteki
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.1
cc4xgvtpry1oc8z
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.1
nx1rid
24 Nov 20
Selvita to acquire Fidelta from Galapagos
7:05am
6-K
EX-99.1
g24q5 yx4
16 May 24
Current report (foreign)
8:11am
6-K
EX-99.1
bxymw3b1a23ena5v
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.2
1ipodw
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
pf9q9tdrtrp
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
udh6jt 9g4vn
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
83ztzv4ifn9og6iu1u
29 Oct 19
MOR106 clinical development in atopic dermatitis stopped for futility
6:00am